 |
 Video: What is a Stock Split?
|
|
|
| Cyclacel Pharmaceuticals is a biopharmaceutical company engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin Dependent Kinase 2/9 (CDK2/9) inhibitor, in solid tumors and hematological malignancies. CDKs also provide pivotal functions in the regulation of transcription, DNA repair and metastatic spread. The anti-mitotic program is evaluating plogosertib, a polo-like kinase, or PLK inhibitor, in solid tumors and hematological malignancies. PLK1 is a serine/threonine kinase with a central role in cell division, or the mitotic phase of the cell cycle. According to our Cyclacel Pharmaceuticals stock split history records, Cyclacel Pharmaceuticals has had 4 splits. | |
|
Cyclacel Pharmaceuticals (CYCC) has 4 splits in our Cyclacel Pharmaceuticals stock split history database. The first split for CYCC took place on August 27, 2012. This was a 1 for 7 reverse split, meaning for each 7 shares of CYCC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split. CYCC's second split took place on May 31, 2016. This was a 1 for 12 reverse split, meaning for each 12 shares of CYCC owned pre-split, the shareholder now owned 1 share. For example, a 142.857142857143 share position pre-split, became a 11.9047619047619 share position following the split. CYCC's third split took place on April 15, 2020. This was a 1 for 20 reverse split, meaning for each 20 shares of CYCC owned pre-split, the shareholder now owned 1 share. For example, a 11.9047619047619 share position pre-split, became a 0.595238095238095 share position following the split. CYCC's 4th split took place on December 18, 2023. This was a 1 for 15 reverse split, meaning for each 15 shares of CYCC owned pre-split, the shareholder now owned 1 share. For example, a 0.595238095238095 share position pre-split, became a 0.0396825396825397 share position following the split.
When a company such as Cyclacel Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Cyclacel Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 0.0396825396825397 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cyclacel Pharmaceuticals shares, starting with a $10,000 purchase of CYCC, presented on a split-history-adjusted basis factoring in the complete Cyclacel Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/28/2014 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$12,060.00 |
|
| End price/share: |
$2.30 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.98% |
|
| Average Annual Total Return: |
-57.54% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1.91 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 08/27/2012 | 1 for 7 | | 05/31/2016 | 1 for 12 | | 04/15/2020 | 1 for 20 | | 12/18/2023 | 1 for 15 |
|
|
Free CYCC Email Alerts:
